Explore

Reuters Reuters
Novartis twin drug setbacks pile pressure on pipeline, CEO

Novartis twin drug setbacks pile pressure on pipeline, CEO

By Bhanvi Satija, Dave Graham and Marleen Kaesebier ZURICH, Sept 8 (Reuters) - Novartis said on Tuesday its experimental drug for a muscle-wasting disorder failed a late-stage study, the second major trial setback in days and sending the Swiss drugmaker's shares down about 9% in one of its worst
Reuters Reuters
Novartis twin drug setbacks pile pressure on pipeline and CEO

Novartis twin drug setbacks pile pressure on pipeline and CEO

By Bhanvi Satija, Dave Graham and Marleen Kaesebier ZURICH, Sept 8 (Reuters) - Novartis said on Tuesday its experimental drug for a muscle-wasting disorder failed a late-stage study, the second major trial setback in days and sending the Swiss drugmaker's shares down about 9% in one of its worst
Trendline Trendline
Novartis' Cholesterol Drug Fails to Improve Cardiovascular Outcomes, Impacting U.S. Competitors Amgen and Eli Lilly

Novartis' Cholesterol Drug Fails to Improve Cardiovascular Outcomes, Impacting U.S. Competitors Amgen and Eli Lilly

Novartis' Cholesterol Drug Fails to Improve Cardiovascular Outcomes, Impacting U.S. Competitors Amgen and Eli Lilly
Reuters Reuters
European shares dip as higher crude revives inflation worries; Novartis drags

European shares dip as higher crude revives inflation worries; Novartis drags

Sept 8 (Reuters) - European shares edged lower on Tuesday as rising oil prices fuelled inflation worries and supply concerns over a prolonged Middle East conflict, while Novartis came under pressure after reporting its second drug development setback.
Reuters Reuters
European shares dip on oil-led inflation woes; Novartis set for worst day on record

European shares dip on oil-led inflation woes; Novartis set for worst day on record

By Sudeshna Ghoshal Sept 8 (Reuters) - European shares eased on Tuesday as firmer oil prices fuelled inflation worries and concerns that a Middle East war could disrupt supplies, while Novartis is on track for its worst day on record after reporting a second drug development setback.
Trendline Trendline
Citigroup Upgrades KION and Nordex Stock Ratings to 'Buy', JPMorgan Raises Commerzbank Target

Citigroup Upgrades KION and Nordex Stock Ratings to 'Buy', JPMorgan Raises Commerzbank Target

Citigroup Upgrades KION and Nordex Stock Ratings to 'Buy', JPMorgan Raises Commerzbank Target
Reuters Reuters
Another rate hike, just for insurance: Five questions for the ECB

Another rate hike, just for insurance: Five questions for the ECB

By Dhara Ranasinghe and Stefano Rebaudo LONDON, Sept 7 (Reuters) - The European Central Bank is widely expected to hike interest rates on Thursday, erring on the side of caution as the U.S.-Iran war drags on, keeping oil prices high and raising inflation again.
Reuters Reuters
European shares subdued as surging crude sharpens focus on ECB rate path

European shares subdued as surging crude sharpens focus on ECB rate path

By Medha Singh and Ragini Mathur Sept 7 (Reuters) - European shares closed flat on Monday as rising oil prices following renewed U.S.-Iran tensions fuelled inflation worries, offsetting stronger-than-expected euro zone economic data. The pan-European STOXX 600 ended at 649.9 points.
Trendline Trendline
Jefferies Recommends 'Buy' for Oryzon Genomics, Citing Over 50% Upside Potential

Jefferies Recommends 'Buy' for Oryzon Genomics, Citing Over 50% Upside Potential

Jefferies Recommends 'Buy' for Oryzon Genomics, Citing Over 50% Upside Potential
Reuters Reuters
Wall Street dips as yen, oil gain amid Middle East strife

Wall Street dips as yen, oil gain amid Middle East strife

By Amanda Cooper and Pete Schroeder LONDON/WASHINGTON, Sept 8 (Reuters) - U.S. stocks fell on Tuesday morning, as attacks on energy facilities around the Gulf pushed oil to near $100 a barrel.
Trendline Trendline
Tesla Stock Declines Following Cybercab Launch and Regulatory Scrutiny

Tesla Stock Declines Following Cybercab Launch and Regulatory Scrutiny

Tesla Stock Declines Following Cybercab Launch and Regulatory Scrutiny
USA Today USA Today
Personalized mRNA cancer vaccines offer new hope. We explain

Personalized mRNA cancer vaccines offer new hope. We explain

Personalized mRNA cancer vaccines are showing early success in clinical trials, fueling optimism in the fight against cancer.